Search results
GSK asks to appeal Delaware ruling allowing Zantac cases to go forward
Reuters via Yahoo News· 1 day agoIf Judge Vivian Medinilla of Delaware Superior Court grants the petition, which is also joined by...
GSK: Starts Process for Appeal of Recent Delaware Zantac Ruling
Bloomberg Law· 1 day agoGSK said it has taken the first step to seek appeal of the recent Daubert ruling, made by the Delaware Superior Court, which permits plaintiff expert testimony as part of Zantac litigation in in the state.
Boehringer Ingelheim's survodutide shows breakthrough improvement in liver fibrosis with no...
Benzinga· 5 days agoNews builds on previously announced primary endpoint, which showed up to 83.0% of adults achieved statistically significant improvement in metabolic dysfunction-associated steatohepatitis (MASH) versus placebo
Zealand Pharma says drug shows improvement in fatty liver disease patients
Reuters via AOL· 5 days agoThe company said the data from the trial in patients with metabolic dysfunction-associated steatohepatitis (MASH) was unintentionally and temporarily leaked ahead of its scheduled release on ...
Bayer’s biotech head Jens Vogel says good-bye after 4 years
FierceBiotech· 7 hours agoVogel wrote in a June 11 LinkedIn post announcing his departure. Vogel joined Bayer in March 2020,...
Boehringer’s Weight-Loss Challenger Hits Goals in Liver Study
Bloomberg· 5 days agoA next-generation compound from Boehringer Ingelheim GmbH and Zealand Pharma A/S hit a range of...
A weight loss drug maker's stock is rising on leaked clinical data
Quartz· 5 days agoZealand Pharma’s stock initially jumped 7% on Thursday, after results from a phase 2 clinical trial...
Zealand Pharma Shares Jump After Drug Shows Promise in Liver Trial
Market Watch· 5 days agoAt 1544 GMT, shares of Zealand Pharma traded 6.6% higher at DKK651.00. The Danish pharmaceutical company said Thursday that drug survodutide--licensed to Germany's Boehringer
Tirzepatide Shows Improvements in MASH Resolution, Fibrosis
Medscape· 2 days agoEncouraging phase 2 results of tirzepatide in the resolution of MASH and improvement in fibrosis...
Experimental GLP-1 med may be breakthrough against fatty liver disease
Medical Xpress· 1 day agoRight now, there's only one drug, resmetirom, approved by the U.S. Food and Drug Administration to...